Pregabalin Capsule
Product Images NDC 80425-0030

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 1

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. The graph compares Pregabalin doses of 75 mg, 150 mg, and 300 mg taken three times a day versus placebo, illustrating trends in patient improvement over a range of pain reduction percentages.*

FDA Label Image

Fig 10

A Kaplan-Meier survival curve comparing Pregabalin and placebo groups over 180 days. The vertical axis shows the estimated percentage of subjects without LTR, and the horizontal axis represents days. The graph illustrates the difference in subject outcomes between Pregabalin and placebo treatments during the study period.*

FDA Label Image

Fig 11

A line graph showing the percentage of subjects improved from baseline to Week 12 based on Percent Improved BOCF. Two curves represent Pregabalin and Placebo treatments, with Pregabalin showing a higher percentage of improvement than Placebo across the measured range.*

FDA Label Image

Fig 12

A line graph depicting the percent of subjects improved over time from baseline to Week 16 following the Brief Oxford Cognitive Screen (BOCF). Two lines represent Pregabalin and Placebo groups, showing a higher percentage improvement for Pregabalin throughout the period.*

FDA Label Image

Fig 2

A line graph comparing percent improvement in pain from baseline against percent of patients improved. It shows two lines labeled 'Pregabalin 100 mg three times a day' and 'Placebo', indicating patient outcomes over varying levels of pain improvement.*

FDA Label Image

Fig 3

A line graph showing percent of patients improved versus percent improvement in pain from baseline, comparing effects of Pregabalin at 75 mg, 150 mg, and 300 mg doses taken twice a day, and a placebo group. The graph illustrates trends in patient improvement over varying levels of pain reduction.*

FDA Label Image

Fig 4

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and a placebo control. The vertical axis shows percent of patients improved, and the horizontal axis shows percent improvement in pain.*

FDA Label Image

Fig 5

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo over the range of pain improvement percentages.*

FDA Label Image

Fig 6

Bar chart comparing responder rates (%) in two clinical studies (E1 and E3) for pregabalin doses versus placebo. The chart shows increasing responder rates with higher pregabalin doses (50 to 600 mg/day), with annotations for dosing frequency (BID or TID) and statistical significance indicated by asterisks.*

FDA Label Image

Fig 7

A line graph displaying seizure reduction as median percentage change from baseline versus dose (mg/day) for Pregabalin across four studies (E1 BID, E2 TID, E3 BID, E3 TID). Data points at placebo (0 mg), 50 mg, 150 mg, 300 mg, and 600 mg doses show increasing seizure reduction with higher doses, with statistically significant p-values noted for each dose comparison.*

FDA Label Image

Fig 9

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg, compared to placebo. The graph illustrates a decline in patient improvement percentage as pain improvement increases across all groups.*

FDA Label Image

Formula

A formula calculation panel showing the equation for creatinine clearance (CLCr), indicating use of patient's age in years, weight in kilograms, serum creatinine in mg/dL, and a factor adjustment for female patients. This appears to be a pharmacokinetic or dosing-related calculation text snippet.*

FDA Label Image

Pregabalin 75mg Cap Qty 60 Ndc 80425 0030

Pregabalin 75 mg capsule label from Advanced Rx of Tennessee, LLC. The label includes NDC 80425-0030, lot number 60PR751223, and expiration date 12/31/2023. The label indicates the product is to be stored at 20° to 25°C (68° to 77°F). It compares the product to Lyrica and is labeled for human prescription use.*

FDA Label Image

Pregabalin 75mg Cap Qty 90 80425 0030

Pregabalin 75 mg capsules packaging label shows the brand Advanced Rx of Tennessee, LLC as the labeler. The label includes product NDC 80425-0030-02 and batch information with lot number 90PN751223 and manufacturer Novadoz Pharmaceuical. Storage instructions specify to keep at 20°-25°C (68°-77°F). The label states the product is to be compared to Lyrica.*

FDA Label Image

Structure

Chemical structure of Pregabalin, displaying its molecular arrangement with amino, carboxyl, and isobutyl groups as characteristic components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.